Lion Point Capital, LP
NEW YORK, NY
$21m in 35 US stocks at the end of 30 June 2026. The top 10 are 55.0% of the money. It changed about 16.8% of the portfolio this quarter.
Value
$21m
Stocks
35
Top 10 share
55.0%
Turnover
16.8%
What changed this quarter
New
Bought for the first time this quarter.
- Cue BiopharmaCUE8.0% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- Cue BiopharmaCUE-100%
Holdings
- Innate Pharma S AIPHA
- Share
- 0.7%
- Value
- $149,318
- Shares
- 81,151
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Cue BiopharmaCUE | 8.0% | $2m | 52,928 | New |
| Praxis Precision MedicinesPRAX | 7.1% | $1m | 4,450 | Held |
| MoonLake ImmunotherapeuticsMLTX | 6.3% | $1m | 67,500 | Held |
| Fennec PharmaceuticalsFENC | 5.8% | $1m | 112,434 | Held |
| Royalty PharmaRPRX | 5.7% | $1m | 21,400 | Held |
| COMPASS PathwaysCMPS | 5.4% | $1m | 80,000 | Held |
| Milestone PharmaceuticalsMIST | 5.3% | $1m | 820,000 | Held |
| Benitec BiopharmaBNTC | 4.0% | $829,560 | 62,000 | Held |
| Syndax PharmaceuticalsSNDX | 3.8% | $786,960 | 36,000 | Held |
| BiohavenBHVN | 3.7% | $769,296 | 51,700 | Held |
| GeronGERN | 3.5% | $739,840 | 578,000 | Held |
| uniQureQURE | 3.2% | $677,082 | 14,700 | Held |
| ArdelyxARDX | 3.1% | $656,115 | 128,650 | Held |
| Lantheus HoldingsLNTH | 2.9% | $610,170 | 5,500 | Held |
| Disc MedicineIRON | 2.8% | $592,434 | 8,100 | Held |
| Sarepta TherapeuticsSRPT | 2.4% | $512,145 | 28,500 | Held |
| HumacyteHUMA | 2.4% | $507,260 | 650,000 | Held |
| Kura OncologyKURA | 2.4% | $504,620 | 46,000 | Held |
| ViatrisVTRS | 2.1% | $439,876 | 27,700 | Held |
| Dyne TherapeuticsDYN | 1.9% | $399,780 | 18,000 | Held |
| BridgeBio PharmaBBIO | 1.8% | $372,400 | 5,000 | Held |
| Edgewise TherapeuticsEWTX | 1.8% | $369,733 | 9,100 | Held |
| Pacira BioSciencesPCRX | 1.6% | $342,495 | 13,500 | Held |
| RegenxbioRGNX | 1.5% | $318,668 | 26,600 | Held |
| Rocket PharmaceuticalsRCKT | 1.4% | $294,120 | 86,000 | Held |
| Janux TherapeuticsJANX | 1.4% | $291,840 | 19,000 | Held |
| Mineralys TherapeuticsMLYS | 1.4% | $283,290 | 10,500 | Held |
| GH ResearchGHRS | 1.3% | $274,176 | 10,200 | Held |
| Seres TherapeuticsMCRB | 1.2% | $249,087 | 31,570 | Held |
| AzentaAZTA | 1.2% | $247,544 | 9,700 | Held |
| Jasper TherapeuticsJSPR | 0.9% | $195,765 | 465,000 | Held |
| InnovivaINVA | 0.9% | $186,222 | 8,200 | Held |
| Innate Pharma S AIPHA | 0.7% | $149,318 | 81,151 | Held |
| Arcutis BiotherapeuticsARQT | 0.7% | $137,655 | 5,250 | Held |
| Spruce BiosciencesSPRB | 0.3% | $54,000 | 1,000 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 41.9% since 30 June 2025.
Where the money is
Health care98.1%
Industrials1.2%
Other0.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.